P.92 UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis

Neuromuscular Disorders - Tập 32 - Trang S80-S81 - 2022
H. Kaminski1, C. Zhao2, G. Meyer zu Horste3, K. O'Connor4, G. Klingelschmitt5, P. Krumova5, S. Bolt6, I. Vodopivec5, H. Murai7
1George Washington University, Washington, USA
2Fudan University, Shanghai, China
3University of Muenster, Muenster, Germany
4Yale University, New Haven, USA
5F. Hoffmann-La Roche Ltd, Basel, Switzerland
6Roche Products, Welwyn Garden City, UK
7Int Univ of Health & Welfare, Narita, Japan